Government caps trade margins on 137 anti-cancer drugs at 30%

The government has changed how prices are calculated for 137 listed anti-cancer medicines. Their trade margin is now capped at 30% of the maximum retail price excluding GST, based on the price at the first sale point. That point may be a stockist or a hospital receiving the medicine directly. The aim is to make essential cancer treatments more affordable.

Manufacturers must calculate revised MRPs and submit them to the National Pharmaceutical Pricing Authority within seven days. The list includes patented medicines such as pembrolizumab, ribociclib and abemaciclib. The new prices take effect on 09.11.2026. GST is added separately to the newly calculated MRP.

The rule also protects patients from price increases caused by the exercise. If a company’s current MRP is already lower than the calculated amount, it must keep the lower price. Manufacturers must widely publish revised prices and maintain present production levels unless NPPA grants permission for reductions or receives information about discontinuation.

MRP means maximum retail price. It is the highest listed price a consumer can be charged, with applicable GST added as required. The price to stockist or price to distributor is the manufacturer’s net selling price to the first trade buyer. The trade margin is the difference between that base price and the MRP, expressed as a share of the MRP under this rule.

The notification sets the trade margin at 30% of MRP excluding GST. For example, if the stockist price is Rs 70, the pre-GST MRP becomes Rs 100. The remaining Rs 30 is the permitted trade margin. The manufacturer calculates the stockist price using net sales divided by the quantity sold.

This limit applies at the first point of sale. If a medicine goes directly to a hospital, the hospital is treated as the stockist or distributor. The manufacturer’s invoice to that hospital is then used for the calculation.

The scale of the problem is unusually large. Experts at a recent NPPA meeting found that non-scheduled anti-cancer medicines carried an average trade mark-up of approximately 170%. In certain cases, the mark-up reached 700%. These figures describe the difference created through the trade chain before the medicine reaches patients.

The government expects the 30% cap to reduce MRPs broadly by 20–70%. The estimated annual saving is approximately ₹2,500 crore. The calculation covers medicines selected as essential for cancer treatment by an expert committee under the Director General of Health Services. It therefore targets a large affordability gap in commonly needed treatments.

Cancer medicines currently have an annual turnover of around ₹12,500 crore. Scheduled cancer medicines, whose prices are already regulated, account for only about ₹2,250 crore. The article also notes that a 2019 exercise cut some MRPs by up to 91%, producing estimated annual savings of ₹984 crore.

The revised MRP uses the manufacturer’s price to the stockist or distributor and applies the capped margin formula. GST is not part of the 30% margin calculation. Instead, applicable GST is added after the new pre-GST MRP has been calculated. This separates the permitted trade margin from the tax component.

Free doses supplied through patient-assistance programmes are excluded from the base sales quantity, provided the company gives NPPA details of the patients. This matters for medicines such as pembrolizumab, where free vials can make up more than half the quantity used in India. Without the exclusion, the calculated price could be inflated because free supplies reduce recorded net sales.

Companies cannot use the formula to raise an already lower price. If the current MRP is below the amount produced by trade-margin rationalisation, that lower MRP must continue. Manufacturers must submit revised prices to NPPA within seven days and make the changes widely known to consumers.

A margin and a mark-up use different denominators. Here, the permitted margin is 30% of the MRP excluding GST. If the MRP is 100, the trade margin is 30 and the price paid to the stockist or distributor is 70. The 30 therefore represents 30% of the final price.

To calculate the increase over the stockist price, divide the 30 difference by 70. The result is 0.4286, or 42.86%. Equivalently, the formula is 70 × [1 + 30 ÷ (100 − 30)] = 100. This is why a 30% margin becomes a 42.86% mark-up when measured from the lower base price.

The distinction prevents confusion about what the cap means. It does not allow a 30% addition to the stockist price. It sets the final pre-GST MRP so that the trade margin equals 30% of that MRP. Applicable GST is then added separately.

The National Pharmaceutical Pricing Authority is the body implementing this order. It has set the trade-margin method, identified the 137 medicines covered by the notification and required manufacturers to submit revised MRPs within seven days. It also uses manufacturer sales and invoice data to calculate the relevant price to stockists, distributors or hospitals.

Enforcement includes financial recovery. A manufacturer that fails to comply must deposit the overcharged amount along with interest. Companies must also widely disseminate revised MRPs so consumers can identify the lower prices. If a hospital receives a medicine directly, its invoice is treated as the relevant first-sale data.

The notification addresses supply risks as well. Manufacturers must maintain present production levels. A company seeking to reduce average monthly production must first obtain NPPA permission. Any manufacturer intending to discontinue one of the listed formulations must furnish information to NPPA. These requirements are meant to prevent price cuts from being followed by shortages or withdrawals.

Patented cancer drugs can remain expensive because the trade-margin cap addresses the distribution layer, not necessarily the manufacturer’s underlying price. A patent can give its holder exclusive market rights for a period, limiting direct competition. With fewer competing products, the manufacturer’s starting price may remain high even after the permitted trade margin falls.

Generic competition usually puts downward pressure on prices because multiple manufacturers can sell equivalent medicines. That pressure may be weaker or unavailable while a patent prevents competing versions. The article specifically includes patented drugs such as pembrolizumab, ribociclib and abemaciclib, but it does not state their patent status beyond calling them patented medicines or explain their individual prices.

Price regulation can still reduce the final bill by controlling the margin between the manufacturer and the patient. However, it may not remove the cost of research, manufacturing or the manufacturer’s chosen base price. The article estimates major savings, but it does not claim that every patented medicine will become affordable for every patient.